Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.

by Bijay S Jaiswal, Vasantharajan Janakiraman, Noelyn M Kljavin, Jeffrey Eastham-Anderson, James E Cupp, Yuxin Liang, David P Davis, Klaus P Hoeflich, Somasekar Seshagiri
Published 2009-05-01